Keymed Biosciences (2162.HK) Earnings Analysis

Keymed Biosciences (2162.HK) next reports earnings on 2026-09-01, consensus EPS 5.31 HKD. Last quarter (2026-03-26) it missed with EPS -1.78617 HKD vs -1.45787 HKD est (-22.5%). It has beaten estimates in 0/1 recent quarters (0%). Trailing P/E -41.87.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 2162.HK next report earnings?

Next earnings date2026-09-01
Consensus EPS estimate5.31 HKD
Revenue estimate0.71B

2162.HK earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-26-1.78617 HKD-1.45787 HKD-22.5%Miss
2025-06-30-0.32636 HKDn/an/an/a
2025-03-24-0.72381 HKDn/an/an/a

Beat rate: 0/1 (0%) over reported quarters with consensus data.

2162.HK valuation and analyst view

Trailing P/E-41.87
Trailing EPS-1.72476 HKD
Price / book7.93
Dividend yield0.00%
Market cap24.63B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Keymed Biosciences (2162.HK)'s next earnings date?

Keymed Biosciences is next scheduled to report on 2026-09-01, with a consensus EPS estimate of 5.31 HKD and revenue estimate of 0.71B.

Did 2162.HK beat earnings last quarter?

In its 2026-03-26 report, 2162.HK posted EPS of -1.78617 HKD versus a -1.45787 HKD estimate — a miss of 22.5%.

What is 2162.HK's earnings track record?

Over the last 1 reported quarters with consensus data, 2162.HK beat estimates 0 times (0%).

What is 2162.HK's current P/E ratio and EPS?

2162.HK trades at a trailing P/E of -41.87 on trailing EPS of -1.7247576674589093 HKD.

What do analysts rate 2162.HK?

2162.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.